Ivermectin has been reported to be a SARS-CoV-2 inhibitor. This activity is believed to be due to the dependence of many different RNA viruses on IMPα / β1 during infection. These reports suggested that the inhibitory activity of ivermectin nuclear transport may be effective against SARS-CoV-2, since they demonstrate that ivermectin has antiviral action against the clinical isolate of SARS-CoV-2 in vitro, with a single dose capable to control viral replication in 24-48 hours. in vitro

Severe Acute Respiratory Syndrome

Ventilation Pneumonitis

Ivermectin 5 MG/ML

Hospital Eurnekian

IVERMECTIN Aspirin Dexametasone and Enoxaparin as Treatment of Covid 19

EVALUATION of Ivermectin Aspirin Dexametasone and Enoxaparin as Treatment of covid19

Considering healing and/or reducing symptoms and severity of initial presentation

Keeping the patient(s) out of ICU, as they do not need mechanical ventilation and/or special intensive care

potential need of reducing or augmenting doses

Outcome of adverse effects to one or more drugs used in the clinical trial

Personal data will remain secret. Only clinical descriptions (age, gender, co-morbidities, evolution, outcomes will be released

Hector E Carvallo

Principal investigator

Eurnekian Public Hospital

COVID19

Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies

Fondation A de Rothschild

Study of the Sars-Cov2 Neuroinvasiveness - COVID19

Fondation Ophtalmologique Adolphe de Rothschild

COVID-19

Guillin OM, Vindry C, Ohlmann T, Chavatte L. Selenium, Selenoproteins and Viral Infection. Nutrients. 2019;11(9):2101. Published 2019 Sep 4. doi:10.3390/nu11092101

Lauretani F, Semba RD, Bandinelli S, et al. Low plasma selenium concentrations and mortality among older community-dwelling adults: the InCHIANTI Study. Aging Clin Exp Res. 2008;20(2):153‐158. doi:10.1007/BF03324762

Cliniques Universitaires de Kinshasa

COVID-19 Lessons Learned: the Outcome of TOMEKA® Project is to Teach

TOMEKA® Project Was Sponsored by the University of Kinshasa: it's an Observational Study by Its Reviewed Documentation

Guyguy K Tshima, MD

Principal Investigator

University of Kinshasa

University Ghent

Université de Montréal

Irradiation of the lungs, administered in a single fraction at the average prescription dose of 0.7 Gy

Participants will undergo irradiation of the lungs, administered in a single fraction at the average prescription dose of 0.7 Gy

Single fraction whole lung radiotherapy

Radiation Oncology Department, ASST SpedaliCivili, Brescia

COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19)

Pilot Study on the Feasibility of Low Dose Radiotherapy for SARS-Cov-2 Pneumonitis (COVID-19 Low Dose Radiotherapy - COLOR 19)

Evaluation of the feasibility of low-dose radiotherapy treatment of SARS-Cov2 pneumonia, for the purpose of the subsequent implementation of a phase II study; lenght of hospital stay will be recorded

Evaluation of the feasibility of low-dose radiotherapy treatment of SARS-Cov2 pneumonia; the number of intensive care unit admissions will be recorded

Variation of the patient's score according to the Brescia COVID-19 Respiratory Severity Scale (minimum value 0, maximum value 8; higher scores mean a worse outcome) with baseline, assessed at 3, 6 and 10 days after treatment.

Evaluation of the safety and tolerance of the low-dose radiotherapy treatment of SARS-Cov2 ( using the CTCAE 5.0 scale)

Variation of the radiological findings, assessed by chest X-ray (performed 3 and 6 days after treatment) and defined according to the Brixia scoring system (0-18 scale, with 18 meaning the worse outcome)

All Individual Participant Data that underlie results in the publication

Stefano Maria Magrini

Prof

Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia

Covid-19 impact in neurological or psychiatric manifestations in patients with Covid-19 infection

patients initially followed for a neurological or psychiatric pathology, suffering from a Covid-19 infection

Neurologic Manifestations

Psychiatric Disorders

CoCo-Neurosciences project is described on the Paris Brain Institute website

Hôpital Pitié Salpétrière

Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders (CoCo-Neurosciences)

Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders: An Observational Study of the Covid-19 Neurological and Psychiatric Manifestations

Frequency of central or peripheral neurological or psychiatric symptoms observed in patients with COVID-19

Impact on neurological or psychiatric disease trajectories assessed by severity scores or subjective progression (improved, stable, impaired) during and after COVID-19 pathology in patients with pre-existing neurological and psychiatric diseases

ageusia/inflamação

IVERMECTIN Aspirin Dexametasone and Enoxaparin as Treatment of Covid 19

Study of the Sars-Cov2 Neuroinvasiveness - COVID19

COVID-19 Lessons Learned: the Outcome of TOMEKA® Project is to Teach

COVID-19 Pneumonitis Low Dose Lung Radiotherapy (COLOR-19)

Cohort of Patients With Covid-19 Presenting Neurological or Psychiatric Disorders (CoCo-Neurosciences)

O mais completo banco de dados de ervas medicinais apoiado pela ciência